- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Menu
Menu
Menu
Menu
Menu
Brand Name :
Imbruvica
Synonyms :
Class :
Anticancer & protein kinase inhibitors
Dosage Forms & Strengths
Tablet, Oral
140 mg
280 mg
420 mg
560 mg
Capsule, Oral
70 mg
140 mg
chronic graft versus host disease
420
mg
Oral
once a day
continued until recurrence of underlying malignancy
chronic lymphocytic leukemia (Cll)
420
mg
Oral
once a day
in combination with Obinutuzumab or rituximab.
560
mg
oral
once a day
continued based of assessment of patient condition.
420
mg
Oral
once a day
in combination with rituximab.
Dose Adjustments
No dose adjustment recommended for renal impairment.
Reduce the dose to 140 mg OD for mild hepatic impairment.
Reduce the dose to 70 mg OD for moderate hepatic impairment.
Avoid use for severe hepatic impairment.
chronic graft versus host disease
420
mg
Orally
once a day
Capsule
continue the dose until recurrence of underlying malignancy
No safe and efficacious dosage is available
chronic graft versus host disease
No safe and efficacious dosage is available
ibrutinib through pharmacodynamic antagonism, reduces the impact of the live rotavirus oral vaccine on the body
may enhance the concentration of serum when combined with ibrutinib
may enhance the concentration of serum when combined with ibrutinib
may enhance the concentration of serum when combined with ibrutinib
may enhance the concentration of serum when combined with ibrutinib
may enhance the concentration of serum when combined with ibrutinib
nafcillin will decrease the effect of action of ibrutinib by affecting enzyme CYP3A4 metabolism.
CYP3A strong enhancers of the small intestine may reduce the bioavailability of ibrutinib
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
the interaction may enhance the hypertensive effect
the interaction with ibrutinib may increase the risk of hemorrhage in patients with low platelets count
the interaction may increase the active metabolite serum concentration of artesunate
ibrutinib may increase the cardiotoxic and hepatotoxic effects of avelumab
the interaction with ibrutinib may enhance the risk of osteonecrosis
may increase the serum level of CYP3A4 substrates
may reduce the serum levels of CYP3A4 substrates
may enhance the serum levels of CYP3A4 substrates
may enhance the serum levels of CYP3A4 substrates
may reduce the serum levels of CYP3A4 substrates
ibrutinib may increase the hepatotoxic effects of pembrolizumab
may increase the hypertension effects of solriamfetol
May have an increasingly adverse effect when combined with Antiplatelet agents
May have an increasingly adverse effect when combined with Antiplatelet agents
May have an increasingly adverse effect when combined with Antiplatelet agents
May have an increasingly adverse effect when combined with Antiplatelet agents
May have an increasingly adverse effect when combined with Antiplatelet agents
it increases the toxicity of antiplatelet agents
it increases the toxicity of antiplatelet agents
it increases the toxicity of antiplatelet agents
may have an increasingly adverse effect when combined with anticoagulants
may have an increasingly adverse effect when combined with anticoagulants
may have an increasingly adverse effect when combined with anticoagulants
may have an increasingly adverse effect when combined with anticoagulants
may have an increasingly adverse effect when combined with anticoagulants
ibrutinib: they may diminish the serum concentration of CYP3A4 Inducers
ibrutinib: they may diminish the serum concentration of CYP3A4 Inducers
ibrutinib: they may diminish the serum concentration of CYP3A4 Inducers
ibrutinib: they may diminish the serum concentration of CYP3A4 Inducers
ibrutinib: they may diminish the serum concentration of CYP3A4 Inducers
it increases the toxicity of antiplatelet agents
may increase the serum concentration of methotrexate
may increase the serum concentration of trimetrexate
the effect of ibrutinib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
it increases the toxicity of antiplatelet agents
it increases the toxicity of antiplatelet agents
may increase the effect of each other through anticoagulation
Frequency defined:
>20-10%
Hypertension (19%)
Skin rash (35%)
Peripheral edema (35%)
Dehydration (12%)
Hyperuricemia (16%)
Hypoalbuminemia (14%)
Abdominal pain (24%)
Constipation (25%)
Dyspepsia (19%)
Stomatitis (29%)
1-10%
Atrial fibrillation (8%)
Cardiac failure (2%)
Weight loss (10%)
Gastrointestinal hemorrhage (4%)
Postmarketing:
Acute hepatic failure
Hepatic cirrhosis
Hepatic failure
Anaphylactic shock
Renal failure syndrome
Pregnancy consideration: ibrutinib is assigned under pregnancy category C based on animal studies.
Lactation: No data available for excretion in breast milk, it should be avoided due to potential side effects.
Pregnancy category:
Patient Information Leaflet
Generic Name: ibrutinib (Rx)
Pronounced: eye-BROO-ti-nib
Why do we use ibrutinib?
Ibrutinib is a second-generation tyrosine kinase inhibitor. It is mostly used for various cancer treatments by stopping the growth of the cancerous cells.
ADVERTISEMENT
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
USA – BOSTON
60 Roberts Drive, Suite 313
North Adams, MA 01247
INDIA – PUNE
7, Shree Krishna, 2nd Floor, Opp Kiosk Koffee, Shirole Lane, Off FC Road, Pune 411004, Maharashtra
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
MASSACHUSETTS – USA
60 Roberts Drive, Suite 313,
North Adams, MA 01247
MAHARASHTRA – INDIA
7, Shree Krishna, 2nd Floor,
Opp Kiosk Koffee,
Shirole Lane, Off FC Road,
Pune 411004, Maharashtra
